A novel immunization approach for dengue infection based on conserved T cell epitopes formulated in calcium phosphate nanoparticles

References

• Restrepo AC, Baker P, Clements AC. National spatial and temporal patterns of notified dengue cases, Colombia 2007–2010. Trop Med Int Health. 2014;19:863-71. doi:10.1111/tmi.12325. PMID:24862214
   PubMed Web of Science ®Google Scholar
• Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, et al. The global distribution and burden of dengue. Nature. 2013;496:504-7. doi:10.1038/nature12060. PMID:23563266
   PubMed Web of Science ®Google Scholar
• Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG, Moyes CL, Farlow AW, Scott TW, Hay SI, et al. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis. 2012;6:e1760. doi:10.1371/journal.pntd.0001760. PMID:22880140
   PubMed Web of Science ®Google Scholar
• Ebi KL, Nealon J. Dengue in a changing climate. Environ Res. 2016;151:115-23. doi:10.1016/j.envres.2016.07.026. PMID:27475051
   PubMed Web of Science ®Google Scholar
• Colon-Gonzalez FJ, Fezzi C, Lake IR, Hunter PR. The effects of weather and climate change on dengue. PLoS Negl Trop Dis. 2013;7:e2503. doi:10.1371/journal.pntd.0002503. PMID:24244765
   PubMed Web of Science ®Google Scholar
• Malavige GN, Ogg GS. T cell responses in dengue viral infections. J Clin Virol. 2013;58:605-11. doi:10.1016/j.jcv.2013.10.023. PMID:24220605
   PubMed Web of Science ®Google Scholar
• Weiskopf D, Sette A. T-cell immunity to infection with dengue virus in humans. Front Immunol. 2014;5:93. doi:10.3389/fimmu.2014.00093. PMID:24639680
   PubMed Web of Science ®Google Scholar
• Simmons, CP, McPherson K, Van Vinh Chau N, Hoai Tam DT, Young P, Mackenzie J, Wills B. Recent advances in dengue pathogenesis and clinical management. Vaccine. 2015;33:7061-8. doi:10.1016/j.vaccine.2015.09.103. PMID:26458808
   PubMed Web of Science ®Google Scholar
• WHO. Dengue: guidelines for diagnosis, treatment, prevention and control – New edition. 2009. Available from: http://www.who.int/tdr/publications/documents/dengue-diagnosis.pdf?ua=1.
   Google Scholar
• Achee NL, Gould F, Perkins TA, Reiner RC Jr, Morrison AC, Ritchie SA, Gubler DJ, Teyssou R, Scott TW. A critical assessment of vector control for dengue prevention. PLoS Negl Trop Dis. 2015;9:e0003655. doi:10.1371/journal.pntd.0003655. PMID:25951103
   PubMed Web of Science ®Google Scholar
• Rodrigo WW, Block OK, Lane C, Sukupolvi-Petty S, Goncalvez AP, Johnson S, Diamond MS, Lai CJ, Rose RC, Jin X, et al. Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype. Virology. 2009;394:175-82. doi:10.1016/j.virol.2009.09.024. PMID:19833371
   PubMed Web of Science ®Google Scholar
• Wu RS, Chan KR, Tan HC, Chow A, Allen JC Jr, Ooi EE. Neutralization of dengue virus in the presence of Fc receptor-mediated phagocytosis distinguishes serotype-specific from cross-neutralizing antibodies. Antiviral Res. 2012;96:340-3. doi:10.1016/j.antiviral.2012.09.018. PMID:23041143
   PubMed Web of Science ®Google Scholar
• Aguiar M, Stollenwerk N, Halstead SB. The risks behind Dengvaxia recommendation. Lancet Infect Dis. 2016;16:882-3. doi:10.1016/S1473-3099(16)30168-2. PMID:27477967
   PubMed Web of Science ®Google Scholar
• Halstead SB, Russell PK. Protective and immunological behavior of chimeric yellow fever dengue vaccine. Vaccine. 2016;34:1643-7. doi:10.1016/j.vaccine.2016.02.004. PMID:26873054
   PubMed Web of Science ®Google Scholar
• Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Muhammad Ismail HI, Reynales H, Limkittikul K, Rivera-Medina DM, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373:1195-206. doi:10.1056/NEJMoa1506223. PMID:26214039
   PubMed Web of Science ®Google Scholar
• Arnon R, Horwitz RJ. Synthetic peptides as vaccines. Curr Opin Immunol. 1992;4:449-53. doi:10.1016/S0952-7915(06)80037-3. PMID:1382452
   PubMed Web of Science ®Google Scholar
• Halstead SB. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis. 1979;140:527-33. doi:10.1093/infdis/140.4.527. PMID:117061
   PubMed Web of Science ®Google Scholar
• Halstead SB, O'Rourke EJ. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med. 1977;146:201-17. doi:10.1084/jem.146.1.201. PMID:406347
   PubMed Web of Science ®Google Scholar
• Mathew A, Rothman AL. Understanding the contribution of cellular immunity to dengue disease pathogenesis. Immunol Rev. 2008;225:300-13. doi:10.1111/j.1600-065X.2008.00678.x. PMID:18837790
   PubMed Web of Science ®Google Scholar
• Bukowski JF, Kurane I, Lai CJ, Bray M, Falgout B, Ennis FA. Dengue virus-specific cross-reactive CD8+ human cytotoxic T lymphocytes. J Virol. 1989;63:5086-91. PMID:2511337
   PubMed Web of Science ®Google Scholar
• Simmons CP, Dong T, Chau NV, Dung NT, Chau TN, Thao le TT, Dung NT, Hien TT, Rowland-Jones S, Farrar J. Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections. J Virol. 2005;79:5665-75. doi:10.1128/JVI.79.9.5665-5675.2005. PMID:15827181
   PubMed Web of Science ®Google Scholar
• Nascimento EJ, Mailliard RB, Khan AM, Sidney J, Sette A, Guzman N, Paulaitis M, de Melo AB, Cordeiro MT, Gil LV, et al. Identification of conserved and HLA promiscuous DENV3 T-cell epitopes. PLoS Negl Trop Dis. 2013;7:e2497. doi:10.1371/journal.pntd.0002497. PMID:24130917
   PubMed Web of Science ®Google Scholar
• de Melo AB, Nascimento EJ, Braga-Neto U, Dhalia R, Silva AM, Oelke M, Schneck JP, Sidney J, Sette A, Montenegro SM, et al. T-cell memory responses elicited by yellow fever vaccine are targeted to overlapping epitopes containing multiple HLA-I and -II binding motifs. PLoS Negl Trop Dis. 2013;7:e1938. doi:10.1371/journal.pntd.0001938. PMID:23383350
   PubMed Web of Science ®Google Scholar
• Piazza P, Campbell D, Marques E, Hildebrand WH, Buchli R, Mailliard R, Rinaldo CR. Dengue virus-infected human dendritic cells reveal hierarchies of naturally expressed novel NS3 CD8 T cell epitopes. Clin Exp Immunol. 2014;177:696-702. doi:10.1111/cei.12373. PMID:24816171
   PubMed Web of Science ®Google Scholar
• Mathew A, Kurane I, Rothman AL, Zeng LL, Brinton MA, Ennis FA. Dominant recognition by human CD8+ cytotoxic T lymphocytes of dengue virus nonstructural proteins NS3 and NS1.2a. J Clin Invest. 1996;98:1684-91. doi:10.1172/JCI118964. PMID:8833919
   PubMed Web of Science ®Google Scholar
• Yauch LE, Zellweger RM, Kotturi MF, Qutubuddin A, Sidney J, Peters B, Prestwood TR, Sette A, Shresta S. A protective role for dengue virus-specific CD8+ T cells. J Immunol. 2009;182:4865-73. doi:10.4049/jimmunol.0801974. PMID:19342665
   PubMed Web of Science ®Google Scholar
• Zellweger RM, Eddy WE, Tang WW, Miller R, Shresta S. CD8+ T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice. J Immunol. 2014;193:4117-24. doi:10.4049/jimmunol.1401597. PMID:25217165
   PubMed Web of Science ®Google Scholar
• Testa JS, Shetty V, Sinnathamby G, Nickens Z, Hafner J, Kamal S, Zhang X, Jett M, Philip R. Conserved MHC class I-presented dengue virus epitopes identified by immunoproteomics analysis are targets for cross-serotype reactive T-cell response. J Infect Dis. 2012;205:647-55. doi:10.1093/infdis/jir814. PMID:22246683
   PubMed Web of Science ®Google Scholar
• Comber JD, Karabudak A, Huang X, Piazza PA, Marques ET, Philip R. Dengue virus specific dual HLA binding T cell epitopes induce CD8+ T cell responses in seropositive individuals. Hum Vaccin Immunother. 2014;10:3531-43. doi:10.4161/21645515.2014.980210. PMID:25668665
   PubMed Web of Science ®Google Scholar
• Duangchinda T, Dejnirattisai W, Vasanawathana S, Limpitikul W, Tangthawornchaikul N, Malasit P, Mongkolsapaya J, Screaton G. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci U S A. 2010;107:16922-7. doi:10.1073/pnas.1010867107. PMID:20837518
   PubMed Web of Science ®Google Scholar
• Mathew A, Townsley E, Ennis FA. Elucidating the role of T cells in protection against and pathogenesis of dengue virus infections. Future Microbiol. 2014;9:411-25. doi:10.2217/fmb.13.171. PMID:24762312
   PubMed Web of Science ®Google Scholar
• Leclerc C, Dériaud E, Megret F, Briand JP, Van Regenmortel MH, Deubel V. Identification of helper T cell epitopes of dengue virus E-protein. Mol Immunol. 1993;30:613-25. doi:10.1016/0161-5890(93)90072-J. PMID:7683752
   PubMed Web of Science ®Google Scholar
• Gagnon SJ, Zeng W, Kurane I, Ennis FA. Identification of two epitopes on the dengue 4 virus capsid protein recognized by a serotype-specific and a panel of serotype-cross-reactive human CD4+ cytotoxic T-lymphocyte clones. J Virol. 1996;70:141-7. PMID:8523518
   PubMed Web of Science ®Google Scholar
• Rothman AL, Kurane I, Lai CJ, Bray M, Falgout B, Men R, Ennis FA. Dengue virus protein recognition by virus-specific murine CD8+ cytotoxic T lymphocytes. J Virol. 1993;67:801-6. PMID:7678307
   PubMed Web of Science ®Google Scholar
• Lee S, Nguyen MT. Recent advances of vaccine adjuvants for infectious diseases. Immune Netw. 2015;15:51-7. doi:10.4110/in.2015.15.2.51. PMID:25922593
   PubMed Web of Science ®Google Scholar
• Gregory AE, Titball R, Williamson D. Vaccine delivery using nanoparticles. Front Cell Infect Microbiol. 2013;3:13. doi:10.3389/fcimb.2013.00013. PMID:23532930
   PubMed Web of Science ®Google Scholar
• Babai I, Barenholz Y, Zakay-Rones Z, Greenbaum E, Samira S, Hayon I, Rochman M, Kedar E. A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin-neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains. Vaccine. 2001;20:505-15. doi:10.1016/S0264-410X(01)00326-7. PMID:11672916
   PubMed Web of Science ®Google Scholar
• Agger EM, Rosenkrands I, Hansen J, Brahimi K, Vandahl BS, Aagaard C, Werninghaus K, Kirschning C, Lang R, Christensen D, et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One. 2008;3:e3116. doi:10.1371/journal.pone.0003116. PMID:18776936
   PubMed Web of Science ®Google Scholar
• Pandey A, Singh N, Sambhara S, Mittal SK. Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses. Hum Vaccin. 2010;6:178-88. doi:10.4161/hv.6.2.9899. PMID:19875936
   PubMed Web of Science ®Google Scholar
• Reddy ST, van der Vlies AJ, Simeoni E, Angeli V, Randolph GJ, O'Neil CP, Lee LK, Swartz MA, Hubbell JA. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol. 2007;25:1159-64. doi:10.1038/nbt1332. PMID:17873867
   PubMed Web of Science ®Google Scholar
• Ohno S, Kohyama S, Taneichi M, Moriya O, Hayashi H, Oda H, Mori M, Kobayashi A, Akatsuka T, Uchida T, et al. Synthetic peptides coupled to the surface of liposomes effectively induce SARS coronavirus-specific cytotoxic T lymphocytes and viral clearance in HLA-A*0201 transgenic mice. Vaccine. 2009;27:3912-20. doi:10.1016/j.vaccine.2009.04.001. PMID:19490987
   PubMed Web of Science ®Google Scholar
• Karkada M, Weir GM, Quinton T, Sammatur L, MacDonald LD, Grant A, Liwski R, Juskevicius R, Sinnathamby G, Philip R, et al. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses. J Immunother. 2010;33:250-61. doi:10.1097/CJI.0b013e3181c1f1e9. PMID:20445345
   PubMed Web of Science ®Google Scholar
• Pejawar-Gaddy S, Rajawat Y, Hilioti Z, Xue J, Gaddy DF, Finn OJ, Viscidi RP, Bossis I. Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles. Cancer Immunol Immunother. 2010;59:1685-96. doi:10.1007/s00262-010-0895-0. PMID:20652244
   PubMed Web of Science ®Google Scholar
• Almeida JP, Lin AY, Figueroa ER, Foster AE, Drezek RA. In vivo gold nanoparticle delivery of peptide vaccine induces anti-tumor immune response in prophylactic and therapeutic tumor models. Small. 2015;11:1453-9. doi:10.1002/smll.201402179. PMID:25354691
   PubMed Web of Science ®Google Scholar
• Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, Chen Q, Dimopoulos N, Luke T, Murphy R, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A. 2004;101:10697-702. doi:10.1073/pnas.0403572101. PMID:15252201
   PubMed Web of Science ®Google Scholar
• Genton B, Pluschke G, Degen L, Kammer AR, Westerfeld N, Okitsu SL, Schroller S, Vounatsou P, Mueller MM, Tanner M, et al. A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers. PLoS One. 2007;2:e1018. doi:10.1371/journal.pone.0001018. PMID:17925866
   PubMed Web of Science ®Google Scholar
• Berinstein NL, Karkada M, Morse MA, Nemunaitis JJ, Chatta G, Kaufman H, Odunsi K, Nigam R, Sammatur L, MacDonald LD, et al. First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. J Transl Med. 2012;10:156. doi:10.1186/1479-5876-10-156. PMID:22862954
   PubMed Web of Science ®Google Scholar
• Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 2012;18:1254-61. doi:10.1038/nm.2883. PMID:22842478
   PubMed Web of Science ®Google Scholar
• He Q, Mitchell AR, Johnson SL, Wagner-Bartak C, Morcol T, Bell SJ. Calcium phosphate nanoparticle adjuvant. Clin Diagn Lab Immunol. 2000;7:899-903. PMID:11063495
   PubMedGoogle Scholar
• He Q, Mitchell A, Morcol T, Bell SJ. Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2. Clin Diagn Lab Immunol. 2002;9:1021-4. PMID:12204953
   PubMedGoogle Scholar
• Bell SJD, Morcol T, He Q. Therapeutic calcium phosphate particles and methods of manufacture and use. ( Google Patents, 2013).
   Google Scholar
• Morcol T, Nagappan P, Nerenbaum L, Mitchell A, Bell SJ. Calcium phosphate-PEG-insulin-casein (CAPIC) particles as oral delivery systems for insulin. Int J Pharm. 2004;277:91-7. doi:10.1016/j.ijpharm.2003.07.015. PMID:15158972
   PubMed Web of Science ®Google Scholar
• Morcol TNP, Nerenbaum L, Mitchel AR, Bell SJD. Particulate drug delivery systems for protein drugs. In R K. editors. Handbook of particulate drug delivery. Vol. 2. American Scientific Publishers: Stevenson Ranch; 2008. p. 223-41.
   Google Scholar
• Garcia-Contreras L, Morcol T, Bell SJ, Hickey AJ. Evaluation of novel particles as pulmonary delivery systems for insulin in rats. AAPS PharmSci. 2003;5:E9. doi:10.1208/ps050209. PMID:12866936
   PubMedGoogle Scholar
• Morcol T, Weidner JM, Mehta A, Bell SJD, Block T. Calcium phosphate particles as pulmonary delivery system for interferon-α in Mice. AAPS PharmSciTech. ( In press, 2017). doi:10.1208/s12249-017-0847-5. PMID:28752471
   PubMedGoogle Scholar
• Morcol T, Hurst BL, Tarbet EB. Calcium Phosphate Nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice. Vaccine. 2017;35:4569-77.
   Web of Science ®Google Scholar
• Testa JS, Apcher GS, Comber JD, Eisenlohr LC. Exosome-driven antigen transfer for MHC class II presentation facilitated by the receptor binding activity of influenza hemagglutinin. J Immunol. 2010;185:6608-16. doi:10.4049/jimmunol.1001768. PMID:21048109
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Puorro KA, Porgador A, Eisenlohr LC. The induction of virus-specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of epitope are attained. J Immunol. 1999;163:3735-45. PMID:10490969
   PubMed Web of Science ®Google Scholar
• Karttunen J, Sanderson S, Shastri N. Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc Natl Acad Sci U S A. 1992;89:6020-4. doi:10.1073/pnas.89.13.6020. PMID:1378619
   PubMed Web of Science ®Google Scholar
• Bell SJD, He Q MT. Therapeutic calcium phosphate particles and methods of manufacture and use. Vol. 6, 355,271 (ed. patent, U.) (U.S.A., 2002).
   Google Scholar
• Zamze S, Martinez-Pomares L, Jones H, Taylor PR, Stillion RJ, Gordon S, Wong SY. Recognition of bacterial capsular polysaccharides and lipopolysaccharides by the macrophage mannose receptor. J Biol Chem. 2002;277:41613-23. doi:10.1074/jbc.M207057200. PMID:12196537
   PubMed Web of Science ®Google Scholar
• van Doorn E, Liu H, Huckriede A, Hak E. Safety and tolerability evaluation of the use of Montanide ISA51 as vaccine adjuvant: A systematic review. Hum Vaccin Immunother. 2016;12:159-69. doi:10.1080/21645515.2015.1071455. PMID:26378866
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu J, Cheng G. Vaccines and immunization strategies for dengue prevention. Emerg Microbes Infect. 2016;5:e77. doi:10.1038/emi.2016.74. PMID:27436365
   PubMed Web of Science ®Google Scholar
• Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010;33:492-503. doi:10.1016/j.immuni.2010.10.002. PMID:21029960
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Bernhard R, Gérard P, Dramé M, Hanon E, Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One. 2008;3:e1665. doi:10.1371/journal.pone.0001665. PMID:18301743
   PubMed Web of Science ®Google Scholar
• Baras B, Stittelaar KJ, Simon JH, Thoolen RJ, Mossman SP, Pistoor FH, van Amerongen G, Wettendorff MA, Hanon E, Osterhaus AD. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One. 2008;3:e1401. doi:10.1371/journal.pone.0001401. PMID:18167560
   PubMed Web of Science ®Google Scholar
• Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev. 2006;58:1688-713. doi:10.1016/j.addr.2006.09.017. PMID:17118485
   PubMed Web of Science ®Google Scholar
• Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33:941-51. doi:10.1038/nbt.3330. PMID:26348965
   PubMed Web of Science ®Google Scholar
• McKee MD, Roszkowski JJ, Nishimura MI. T cell avidity and tumor recognition: implications and therapeutic strategies. J Transl Med. 2005;3:35. doi:10.1186/1479-5876-3-35. PMID:16174302
   PubMed Web of Science ®Google Scholar
• Knuschke T, Bayer W, Rotan O, Sokolova V, Wadwa M, Kirschning CJ, Hansen W, Dittmer U, Epple M, Buer J, et al. Prophylactic and therapeutic vaccination with a nanoparticle-based peptide vaccine induces efficient protective immunity during acute and chronic retroviral infection. Nanomedicine. 2014;10:1787-98. doi:10.1016/j.nano.2014.06.014. PMID:25014891
   PubMed Web of Science ®Google Scholar
• Knuschke T, Sokolova V, Rotan O, Wadwa M, Tenbusch M, Hansen W, Staeheli P, Epple M, Buer J, Westendorf AM. Immunization with biodegradable nanoparticles efficiently induces cellular immunity and protects against influenza virus infection. J Immunol. 2013;190:6221-9. doi:10.4049/jimmunol.1202654. PMID:23667109
   PubMed Web of Science ®Google Scholar
• Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. Nanomedicine–challenge and perspectives. Angew Chem Int Ed Engl. 2009;48:872-97. doi:10.1002/anie.200802585. PMID:19142939
   PubMed Web of Science ®Google Scholar
• Sokolova V, Knuschke T, Kovtun A, Buer J, Epple M, Westendorf AM. The use of calcium phosphate nanoparticles encapsulating Toll-like receptor ligands and the antigen hemagglutinin to induce dendritic cell maturation and T cell activation. Biomaterials. 2010;31:5627-33. doi:10.1016/j.biomaterials.2010.03.067. PMID:20417963
   PubMed Web of Science ®Google Scholar
• Brust M, Walker M, Bethell D, Schiffrin DJ, Whyman R. Synthesis of thiol derivatised gold nanoparticles in a two-phase liquid/liquid system. Chem Soc Chem Commun. 1994;6:801-2. doi:10.1039/C39940000801
   Google Scholar
• Maitre N, Brown JM, Demcheva M, Kelley JR, Lockett MA, Vournakis J, Cole DJ. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination. Clin Cancer Res. 1999;5:1173-82. PMID:10353754
   PubMed Web of Science ®Google Scholar
• Pedrali A, Bleve M, Capra P, Jonsson T, Massolini G, Perugini P, Marrubini G. Determination of N-acetylglucosamine in cosmetic formulations and skin test samples by hydrophilic interaction liquid chromatography and UV detection. J Pharm Biomed Anal. 2015;107:125-30. doi:10.1016/j.jpba.2014.12.014. PMID:25589383
   PubMed Web of Science ®Google Scholar
• Maverakis E, Kim K, Shimoda M, Gershwin ME, Patel F, Wilken R, Raychaudhuri S, Ruhaak LR, Lebrilla CB. Glycans in the immune system and The altered glycan theory of autoimmunity: a critical review. J Autoimmun. 2015;57:1-13. doi:10.1016/j.jaut.2014.12.002. PMID:25578468
   PubMed Web of Science ®Google Scholar
• Demaria S, Bhardwaj N, McBride WH, Formenti SC. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys. 2005;63:655-66. doi:10.1016/j.ijrobp.2005.06.032. PMID:16199306
   PubMed Web of Science ®Google Scholar
• Shetty V, Sinnathamby G, Nickens Z, Shah P, Hafner J, Mariello L, Kamal S, Vlahović G, Lyerly HK, Morse MA, et al. MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response. J Proteomics. 2011;74:728-43. doi:10.1016/j.jprot.2011.02.020. PMID:21362506
   PubMed Web of Science ®Google Scholar
• Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004;294:15-22. doi:10.1016/j.jim.2004.08.008. PMID:15604012
   PubMed Web of Science ®Google Scholar
• Fukuda M. Lysosomal membrane glycoproteins. Structure, biosynthesis, and intracellular trafficking. J Biol Chem. 1991;266:21327-30. PMID:1939168
   PubMed Web of Science ®Google Scholar